DNTH 株価分析 — Dianthus Therapeutics Inc. (Healthcare >> Biotechnology)
DNTH に関するよくある質問
DNTHのPER(株価収益率)は?
Dianthus Therapeutics Inc.(DNTH)は現在PER 59.70倍で取引されています。
DNTHのROE(自己資本利益率)は?
Dianthus Therapeutics Inc.のROEは-0.94%です。
DNTHの配当利回りは?
Dianthus Therapeutics Inc.の配当利回りは0.00%です。
DNTHの品質スコア(Quality Score)は?
当社のAIはDNTHの総合財務品質を100点中23点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
DNTHは今が買い時ですか?
当社AIのタイミングスコアは100点中91点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
DNTHはどのセクターに属しますか?
Dianthus Therapeutics Inc.はHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
DNTH AI Analysis Summary
Our AI summary for DNTH: Dianthus Therapeutics Inc. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 59.70, ROE of -0.94%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 106.02
Price
-0.90
(-0.84%)
Day Change
|
|
|---|
DNTH, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) but テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/Eが高い。割高銘柄。
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 75 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 106.02 |
| PBV / Sector |
4.87 / 44,219.29
|
| Earning Per Share | -0.21 |
| PE / Sector |
59.70 / 19.28
|
| PEG or PE/Growth / Sector |
18.26 / 1.23
|
| Average 1M Daily Value |
88.51 M
|
| Average 1W Daily Value |
86.81 M
|
| Timing Factors |
|
71% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
60% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-04 08:01:24 |
| Symbol | DNTH |
| Name | DIANTHUS THERAPEUTICS INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 54.67 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 5,844.91 / 9,645.64 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 7 Times Square, New York, NY, United States, 10036
Phone: 929 999 4055
Website: https://dianthustx.com
Employees: 92
Sector: Healthcare >> Biotechnology
Description: Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google